See More

See the difference

See the difference

Aspaveli provides meaningful improvements in clinical outcomes vs eculizumab in patients with persistent anaemia despite C5i treatment1

85% / 15%

Mean change from baseline in ARC (x109 cells/L) (±SE)

See improvements in patients’ ARC levels (±SE)

Mean change from baseline in FACIT-Fatigue score (±SE)

+9.2 / -2.7

This difference was considered to be clinically significant, but non-inferiority was not assessed because of the pre-specified statistical hierarchical testing rules. 73% of patients in the Aspaveli group had at least a 3-point increase in FACIT–F scores at week 16, as compared with 0% in the eculizumab group; a 3-point change is considered clinically significant.1

ARC=absolute reticulocyte count; CI=confidence interval; FACIT=Functional Assessment of Chronic Illness Therapy.

Reference: 1. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384:1028–1037.